LG 101506: High-Purity RXR Modulator for Nuclear Receptor Signaling Research

Executive Summary: LG 101506 (SKU B7414) is a chemically defined RXR modulator developed by APExBIO, with a molecular weight of 420.53 and purity of 98.00% (product page). It exhibits high solubility in DMSO (42.05 mg/ml) and ethanol (21.03 mg/ml), supporting diverse assay formats. RXR signaling is central to metabolic regulation and cancer biology, making LG 101506 valuable for mechanistic and translational studies (J. Zhang et al., 2022). The compound is intended exclusively for research use, with best practices including storage at -20°C and prompt use of solutions. LG 101506 advances the reproducibility and specificity of RXR pathway research (contrast article).

Biological Rationale

The Retinoid X Receptor (RXR) is a nuclear receptor that forms heterodimers with multiple partners, including Peroxisome Proliferator-Activated Receptors (PPARs) and Liver X Receptors (LXRs) (Zhang et al., 2022). RXR signaling modulates gene expression linked to lipid metabolism, glucose homeostasis, and cell proliferation. Dysregulation of RXR pathways is implicated in metabolic disorders and various cancers, including immune-cold tumors such as triple-negative breast cancer (TNBC). RXR modulation influences immune checkpoint expression, notably PD-L1, impacting tumor immune evasion. LG 101506 enables selective interrogation of these pathways due to its high purity and defined mechanism (see related analysis).

Mechanism of Action of LG 101506

LG 101506 is a small molecule ligand targeting the ligand-binding domain of RXR. Upon binding, it modulates the conformational state of RXR, affecting heterodimerization and recruitment of co-regulators. This allosteric control alters downstream transcriptional activity in RXR-regulated genes. Experimental evidence highlights RXR's role in regulating PD-L1 stability and immune checkpoint pathways, relevant for TNBC models (primary DOI). The molecular structure of LG 101506—(2E,4E,6Z)-7-(3,5-di-tert-butyl-2-(2,2-difluoroethoxy)phenyl)-3-methylocta-2,4,6-trienoic acid—confers specificity for RXR with minimal off-target nuclear receptor activity (APExBIO data sheet). The compound is an off-white solid, stable under recommended storage (-20°C), and supports rapid dissolution in DMSO and ethanol for cell-based and biochemical assays.

Evidence & Benchmarks

• LG 101506 exhibits ≥98% chemical purity by HPLC and NMR, supporting reproducible RXR pathway modulation (APExBIO).
• Solubility in DMSO reaches 42.05 mg/ml; in ethanol, 21.03 mg/ml, enabling use in high-throughput or dose-response studies (product page).
• RXR modulation influences the stability of PD-L1 via transcriptional and post-translational mechanisms in cancer models (Zhang et al., 2022).
• Post-translational regulation of PD-L1 through RXR-linked pathways enables combinatorial strategies with immune checkpoint inhibitors (see Fig. 1, Zhang et al., 2022).
• Proper storage (solid at -20°C, solutions used promptly) maintains compound stability and functional integrity for all research applications (APExBIO).

Applications, Limits & Misconceptions

LG 101506 is applied in RXR signaling pathway research, metabolic regulation, and models of nuclear receptor-related disease, including cancer biology and immune checkpoint studies. Its chemical consistency supports quantitative assays and mechanistic dissection of RXR's role in gene regulation. Studies in TNBC highlight RXR's capacity to modulate immune checkpoint pathways, notably PD-L1, informing therapeutic strategies (further strategic context). LG 101506 extends prior work by enabling precision in pathway interrogation where standard RXR ligands may lack selectivity or stability.

Common Pitfalls or Misconceptions

• LG 101506 is not intended for diagnostic or therapeutic (human/clinical) use; it is for research use only (APExBIO).
• Long-term storage of solutions can degrade compound integrity; always prepare fresh solutions for each experimental run.
• Over-interpretation of RXR modulation effects in non-RXR-dependent pathways can lead to confounded results—validate receptor specificity using controls.
• Data from immune-cold tumor models (e.g., TNBC) may not generalize to all cancer types due to differential RXR pathway activation.
• Solubility parameters are specific to DMSO and ethanol; use of other solvents may yield unpredictable results or compound precipitation.

Workflow Integration & Parameters

For optimal results, dissolve LG 101506 in DMSO (≤42.05 mg/ml) or ethanol (≤21.03 mg/ml) at room temperature, and store aliquots at -20°C. Avoid repeated freeze-thaw. Use freshly prepared solutions. In cell-based assays, titrate concentrations based on cell type and endpoint, typically starting from 0.1–10 μM. Include vehicle controls (DMSO or ethanol alone) in all experimental designs. LG 101506 is shipped with blue ice for small molecule format or dry ice for nucleotides to ensure stability. For reproducibility guidance and troubleshooting, see Practical Solutions for RXR Signal...—this dossier updates that piece by detailing LG 101506's latest performance data and application boundaries.

For advanced immunometabolic and translational oncology models, LG 101506 facilitates selective RXR pathway interrogation, as outlined in LG 101506: Advanced RXR Modulation for Immunometabolic Research. This article extends those findings by providing direct guidance on workflow integration and common pitfalls.

Conclusion & Outlook

LG 101506, supplied by APExBIO, is a validated, high-purity RXR modulator optimized for nuclear receptor research. Its robust solubility, storage stability, and specificity support advanced studies in RXR signaling, metabolism regulation, and nuclear receptor-related cancer models. Proper use of LG 101506 enables high-confidence dissection of RXR-mediated pathways, including immune checkpoint regulation and metabolic gene expression. As RXR biology continues to inform translational therapies, LG 101506's precise modulation will be pivotal in developing combinatorial strategies and overcoming resistance in immune-cold tumor contexts (see more on strategic innovation in RXR research).